StreetInsider.com News Articles

Form S-4/A Cyclerion Therapeutics,

Tue, 09 Jun 2026 16:09:00 -0400

http://archive.fast-edgar.com/20260609/A522R62EZZ2R6ZZ222TQ2ZYML7RDEZ22X282

Filed on: June 9, 2026

Form S-4/A Cyclerion Therapeutics,

Tue, 09 Jun 2026 16:09:00 -0400

http://archive.fast-edgar.com/20260609/A522R62EZZ2R6ZZ222TQ2ZYML7RDEZ22X282

Filed on: June 9, 2026

Form 10-Q Cyclerion Therapeutics, For: Mar 31

Tue, 12 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260512/26478129.html

Form 10-Q Cyclerion Therapeutics, For: Mar 31

Tue, 12 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260512/26478129.html

Form SCHEDULE 13G Cyclerion Therapeutics, Filed by: FMR LLC

Thu, 07 May 2026 10:42:00 -0400

si-local-file:///var/storage/secattach/20260507/26450675.html

Form SCHEDULE 13G Cyclerion Therapeutics, Filed by: FMR LLC

Thu, 07 May 2026 10:42:00 -0400

si-local-file:///var/storage/secattach/20260507/26450675.html

Form 10-K/A Cyclerion Therapeutics, For: Dec 31

Thu, 30 Apr 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260430/26401524.html

Form 10-K/A Cyclerion Therapeutics, For: Dec 31

Thu, 30 Apr 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260430/26401524.html

Form S-4 Cyclerion Therapeutics,

Mon, 20 Apr 2026 06:02:00 -0400

http://archive.fast-edgar.com/20260420/AL2ZW22DZZ2RB2Z222T92CYQOPPQZZ22N882

Filed on: April 20, 2026

Form S-4 Cyclerion Therapeutics,

Mon, 20 Apr 2026 06:02:00 -0400

http://archive.fast-edgar.com/20260420/AL2ZW22DZZ2RB2Z222T92CYQOPPQZZ22N882

Filed on: April 20, 2026

Form 425 Cyclerion Therapeutics, Filed by: Cyclerion Therapeutics, Inc.

Wed, 01 Apr 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260401/26259619.html

Form 425 Cyclerion Therapeutics, Filed by: Cyclerion Therapeutics, Inc.

Wed, 01 Apr 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260401/26259619.html

Form 8-K Cyclerion Therapeutics, For: Apr 01

Wed, 01 Apr 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260401/26259259.html

Form 8-K Cyclerion Therapeutics, For: Apr 01

Wed, 01 Apr 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260401/26259259.html

Cyclerion and Korsana announce $380 million merger deal

Wed, 01 Apr 2026 07:05:54 -0400

Cyclerion Therapeutics Inc. (NASDAQ: CYCN) and privately-held Korsana Biosciences Inc. announced they have entered into a definitive merger agreement for an all-stock transaction. The combined company will operate as Korsana Biosciences Inc. and trade on Nasdaq under the ticker symbol "KRSA."

Korsana has secured commitments for approximately $380 million in private investment from a syndicate of investors led by Fairmount and Venrock Healthcare Capital Partners. The financing includes participation from General Atlantic, TCGX, Forbion, Wellington Management, and other investment firms.

The financing is expected to close immediately prior to completion of the merger. The combined company's cash balance at closing is anticipated

Cyclerion and Korsana announce $380 million merger deal

Wed, 01 Apr 2026 07:05:54 -0400

The financing is expected to close immediately prior to completion of the merger. The combined company's cash balance at closing is anticipated

Cyclerion and Korsana announce $380 million merger deal

Wed, 01 Apr 2026 07:05:54 -0400

The financing is expected to close immediately prior to completion of the merger. The combined company's cash balance at closing is anticipated

Cyclerion and Korsana announce $380 million merger deal

Wed, 01 Apr 2026 07:05:54 -0400

The financing is expected to close immediately prior to completion of the merger. The combined company's cash balance at closing is anticipated

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Wed, 01 Apr 2026 07:05:00 -0400

Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases

Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease

Concurrent private financing of approximately $380 million expected to fund Korsana’s operations into 2029, including multiple clinical trial data readouts expected in 2027

Conference call scheduled for April 1, 2026, at 8:00 am ET

WALTHAM, Mass.--(BUSINESS WIRE)-- Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and developing novel therapies to reduce the

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Wed, 01 Apr 2026 07:05:00 -0400

Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases

Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease

Concurrent private financing of approximately $380 million expected to fund Korsana’s operations into 2029, including multiple clinical trial data readouts expected in 2027

Conference call scheduled for April 1, 2026, at 8:00 am ET

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Wed, 01 Apr 2026 07:05:00 -0400

Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases

Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease

Concurrent private financing of approximately $380 million expected to fund Korsana’s operations into 2029, including multiple clinical trial data readouts expected in 2027

Conference call scheduled for April 1, 2026, at 8:00 am ET

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Wed, 01 Apr 2026 07:05:00 -0400

Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases

Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease

Concurrent private financing of approximately $380 million expected to fund Korsana’s operations into 2029, including multiple clinical trial data readouts expected in 2027

Conference call scheduled for April 1, 2026, at 8:00 am ET

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Wed, 01 Apr 2026 07:05:00 -0400

Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases

Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease

Concurrent private financing of approximately $380 million expected to fund Korsana’s operations into 2029, including multiple clinical trial data readouts expected in 2027

Conference call scheduled for April 1, 2026, at 8:00 am ET

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Wed, 01 Apr 2026 07:05:00 -0400

Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases

Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease

Concurrent private financing of approximately $380 million expected to fund Korsana’s operations into 2029, including multiple clinical trial data readouts expected in 2027

Conference call scheduled for April 1, 2026, at 8:00 am ET

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Wed, 01 Apr 2026 07:05:00 -0400

Combined company to operate as Korsana Biosciences and to advance Korsana’s potential best-in-class therapeutics to treat neurodegenerative diseases

Korsana’s lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease

Concurrent private financing of approximately $380 million expected to fund Korsana’s operations into 2029, including multiple clinical trial data readouts expected in 2027

Conference call scheduled for April 1, 2026, at 8:00 am ET